Research progress in perioperative immunotherapy for non-small cell lung cancer
- VernacularTitle:非小细胞肺癌围手术期免疫治疗的研究进展
- Author:
Yuanyuan XU
1
;
Feng MAO
1
;
Xiaoke CHEN
1
;
Qiang TAN
1
;
Qingquan LUO
1
Author Information
1. Department of Oncology Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
non-small cell lung cancer;
perioperative stage;
surgery;
programmed death-ligand 1 (PD-L1);
circulating tumor DNA (ctDNA）
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(02):318-325
- CountryChina
- Language:Chinese
-
Abstract:
It is very limited that the benefit of perioperative chemotherapy in early non-small cell lung cancer (NSCLC), and the 5-year survival rate is only 5% higher than surgery. Antibodies that block programmed cell death protein 1/programmed death-ligand 1 significantly improve the survival of advanced NSCLC. The value of immunotherapy in early NSCLC is also being explored. This paper firstly summarized and analyzed the progress of immunotherapy in the perioperative period of NSCLC. Secondly, the safety and feasibility of surgical resection after neoadjuvant immunotherapy were discussed. Finally, the clinical value of different therapeutic efficacy prediction indicators was summarized, in order to clarify the current status of immunotherapy in the perioperative period, so as to improve the clinical benefits of early NSCLC patients.
